Published in J Leukoc Biol on August 28, 2015
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
The biology of Hodgkin's lymphoma. Nat Rev Cancer (2008) 3.31
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J (1998) 3.01
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood (2006) 2.90
The role of cytokines in classical Hodgkin lymphoma. Blood (2002) 2.86
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med (1996) 2.75
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood (2003) 2.47
Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A (1994) 2.41
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A (2007) 2.31
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood (2008) 2.15
Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood (2002) 2.03
Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood (2002) 1.91
Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood (2012) 1.82
High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol (1999) 1.78
In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease. Blood (1982) 1.71
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood (2014) 1.71
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res (2006) 1.66
Molecular pathways of adhesion in spontaneous rosetting of T-lymphocytes to the Hodgkin's cell line L428. Cancer Res (1988) 1.59
Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med (1999) 1.44
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol (2007) 1.39
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood (2006) 1.35
Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program (2005) 1.35
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol (2008) 1.29
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol (2005) 1.16
Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res (2006) 1.15
Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol (2013) 1.15
Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res (2001) 1.14
RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. Blood (2007) 1.13
Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood (1994) 1.12
Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int J Biochem Cell Biol (2007) 1.12
Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood (2007) 1.12
Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood (2007) 1.12
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res (2006) 1.11
Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol (2006) 1.08
HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens (2008) 1.06
Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol (2007) 1.05
Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer (2008) 1.04
Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood (1999) 1.04
Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer (2003) 1.04
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood (2013) 1.02
Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Source and site of action of tumor necrosis factor alpha. Am J Pathol (1991) 1.00
Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood (2001) 0.99
Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood (2005) 0.99
New insights in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program (2012) 0.98
Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood (1996) 0.98
CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol (1995) 0.98
Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood (1995) 0.96
Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology (2000) 0.96
Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer (2009) 0.96
Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Clin Pathol (2006) 0.96
Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol (2001) 0.96
The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood (1993) 0.95
Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res (2012) 0.95
The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Invest (2008) 0.92
The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia (2014) 0.91
Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J Pathol (2000) 0.89
Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol (2004) 0.89
Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol (2007) 0.89
Reed-Sternberg/lymphocyte rosette: lymphocyte subpopulations as defined by monoclonal antibodies. J Clin Pathol (1984) 0.88
The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leuk Lymphoma (2011) 0.86
Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am J Pathol (2002) 0.85
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother (2008) 0.85
Bauhinia purpurea--a new paraffin section marker for Reed-Sternberg cells of Hodgkin's disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30). Am J Pathol (1992) 0.84
Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J Clin Pathol (1995) 0.84
Fas ligand expression in Hodgkin lymphoma. Am J Surg Pathol (2001) 0.84
Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res (2003) 0.84
Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients. Blood (1990) 0.83
The role of interleukin-3 in classical Hodgkin's disease. Leuk Lymphoma (2005) 0.82
Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease. Leukemia (1997) 0.81
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol (2013) 0.81
Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines. Leuk Res (2007) 0.80
The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells. Leukemia (1996) 0.80
Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice. Blood (1993) 0.80
The patterns of IL2, IFN-gamma, IL4 and IL5 gene expression in Hodgkin's disease and reactive lymph nodes are similar. Haematologica (1998) 0.79
Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease. Pathol Int (1998) 0.79
Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. Blood (2000) 0.79
The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma. Pathology (2003) 0.78
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Ann Hematol (2013) 0.77
Flow cytometry CD4(+)CD26(-)CD38(+) lymphocyte subset in the microenvironment of Hodgkin lymphoma-affected lymph nodes. Ann Hematol (2014) 0.76
Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells. J Cancer Res Clin Oncol (2017) 0.75
Erratum to: Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells. J Cancer Res Clin Oncol (2017) 0.75